Lund University

Denna sida på svenska This page in English

Novel immuno-oncological strategies for improved cancer therapy

Principle investigator Kristina Lundberg



Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy, based on the tremendous effects seen in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients have a therapeutic response. The research focus of this position is to identify and explore novel immune cells targets in cancer.


The overall aim of our research is to identify and exploit novel drug targets that enables the immune system to efficiently eradicate cancer cells, and to translate those innovation into novel clinical strategies. We have established a distinctive pipeline for transcriptomic studies down to single-cell level of tumour-infiltrating immune cells using RNA sequencing, as well as for bioinformatical analysis of the data, to pinpoint novel potential cell surface drug targets on specific immune cells. We employ this pipeline to identify novel targets on e.g. specific T-cells and on cells that regulate T-cell activity, such as myeloid cells. Furthermore, we explore immune and cancer cell targets in order to combine both cancer immunotherapy and radiation treatment. Through an extensive network of national and international collaborators we explore these cells in several different cancer indications, including acute myeloid leukaemia, bladder cancer and lung cancer.


We now offer a highly motivated postdoctoral candidate to join our team. Depending on project progression, there will be possibilities to perform research from target discovery, based e.g. on transcriptomic studies, to functional in vitro studies and beyond, using antibodies developed in-house against identified targets. Furthermore, spatial profiling to assess cell and target distribution within tissue may be part of the project. We work closely together with clinicians at Skåne University Hospital, enabling access to samples from cancer patients, and also together with the industry with Alligator Bioscience being a collaborator within the projects.


Key requirements:

  • PhD in immunology or tumor immunology
  • experience in primary cell work and in vitro assays
  • very good communication skills and very good oral and written proficiency in English.
  • strong publication record.


Advantageous skills:

  • deep knowledge in immunology, preferably focused on human T-cells and/or myeloid cells
  • knowledge within the field of immuno-oncology/cancer immunotherapy
  • experience in immunologically relevant in vitro assays  (flow cytometry and cell sorting, IHC/IF, spatial profiling, ELISA/Luminex assays)
  • experience in analysing quantitative omics data, using biostatistical methods, independently or in collaboration with bioinformaticians depending on the complexity.
  • ability to summarize and present scientific data, both orally and in writing (in English).
  • experience in using R or Python for analysis purposes.


Website: Kristina Lundberg

Partners: Region Skåne (health care) and Alligator Bioscience.